levodopa has been researched along with buspirone in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 1 |
| German, DC; Matthews, RT; McMillen, BA; Sanghera, MK; Shepard, PD | 1 |
| Bonifati, V; Cipriani, R; Fabrizio, E; Meco, G; Vanacore, N | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Brochu, C; Guertin, PA | 1 |
| Berger, SP; Brudney, EG; Foley, K; Johnson, SW; Meshul, CK; Paquette, MA | 1 |
| Guertin, PA; Rouleau, P; Ung, RV | 2 |
| Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M | 1 |
| Adamaszek, M; Beck, J; Ohm, S; Schwarz, J; Strecker, K; Wegner, F | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E | 1 |
| Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V | 1 |
| Bain, P; Brooks, DJ; Kiferle, L; Loane, C; Molloy, S; Piccini, P; Politis, M; Turkheimer, FE; Wu, K | 1 |
| Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N | 1 |
| Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L | 1 |
| Guertin, PA | 1 |
| Dyck, S; Guertin, PA; Kia, M; Matte, G; Mongeon, D; Prince, F; Radhakrishna, M; Roberts, M; Steuer, I; Vaillancourt, M | 1 |
| Danilchenko, V; Dhar, A; Matiashova, L; Miranda, AV; Papakosta, V; Tsagkaris, C; Zacharopoulou, L | 1 |
| Aristieta, A; Bengoetxea, H; Lafuente, JV; Miguelez, C; Requejo, C; Ugedo, L; Vegas-Suárez, S | 1 |
| Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M | 1 |
2 review(s) available for levodopa and buspirone
| Article | Year |
|---|---|
Rationale for Assessing Safety and Efficacy of Drug Candidates Alone and in Combination with Medical Devices: The Case Study of SpinalonTM.
Topics: Animals; Buspirone; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Locomotion; Motor Neurons; Randomized Controlled Trials as Topic; Spinal Cord Injuries | 2017 |
Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Topics: Angelman Syndrome; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Buspirone; Diet, Ketogenic; Dietary Supplements; Disease Models, Animal; Gene Silencing; Genetic Therapy; Humans; Levodopa; Mice; Minocycline; Neurons; Signal Transduction; Topoisomerase I Inhibitors; Ubiquitin-Protein Ligases | 2020 |
3 trial(s) available for levodopa and buspirone
| Article | Year |
|---|---|
Buspirone in levodopa-induced dyskinesias.
Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Raclopride; Radionuclide Imaging; Radiopharmaceuticals; Serotonergic Neurons; Serotonin 5-HT1 Receptor Agonists; Synapses; Treatment Outcome | 2014 |
Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury.
Topics: Administration, Oral; Adult; Buspirone; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Spinal Cord Injuries; Young Adult | 2017 |
20 other study(ies) available for levodopa and buspirone
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
Topics: Animals; Anti-Anxiety Agents; Apomorphine; Buspirone; Corpus Striatum; Dopamine; Female; Kinetics; Levodopa; Male; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Synaptosomes; Tyrosine 3-Monooxygenase | 1983 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Preliminary evidence of safety following administration of L-DOPA and buspirone in an incomplete monoplegic patient.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Buspirone; Central Nervous System Venous Angioma; Cerebral Palsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Leg; Levodopa; Male; Movement; Postoperative Complications; Regional Blood Flow; Treatment Outcome | 2009 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Piperazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Sigma-1 Receptor | 2009 |
Oral administration of a tri-therapy for central pattern generator activation in paraplegic mice: proof-of-concept of efficacy.
Topics: Administration, Oral; Animals; Biological Clocks; Buspirone; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Gait Disorders, Neurologic; Levodopa; Male; Mice; Paraplegia; Serotonin Receptor Agonists; Spinal Cord | 2010 |
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Functional and physiological effects of treadmill training induced by buspirone, carbidopa, and L-DOPA in clenbuterol-treated paraplegic mice.
Topics: Adipose Tissue; Analysis of Variance; Animals; Biomechanical Phenomena; Body Composition; Body Weight; Bone Density; Buspirone; Densitometry; Disease Models, Animal; Dopamine Agents; Exercise Test; Exercise Therapy; Histocompatibility Antigens; Levodopa; Male; Mice; Motor Activity; Muscle Fibers, Skeletal; Muscle, Skeletal; Paraplegia; Recovery of Function; Sacrococcygeal Region; Serotonin Receptor Agonists; Spinal Cord Injuries | 2012 |
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Topics: Animals; Benzimidazoles; Buspirone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; RGS Proteins; Serotonin Antagonists; Serotonin Receptor Agonists | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2015 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus | 2016 |
The effect of 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Entopeduncular Nucleus; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A | 2021 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |